Navidea Biopharmaceuticals, Inc.
NAVB · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $8,913 | $4,438 | $8,490 | $6,799 |
| - Cash | $3,865 | $6,144 | $34 | $1,996 |
| + Debt | $1,260 | $1,339 | $2,318 | $2,436 |
| Enterprise Value | $6,308 | -$367 | $10,774 | $7,239 |
| Revenue | $0 | $0 | $0 | $1 |
| % Growth | – | – | -100% | – |
| Gross Profit | -$36 | -$36 | $0 | -$49 |
| % Margin | – | – | – | -8,102.6% |
| EBITDA | -$2,104 | -$2,401 | -$1,186 | -$3,200 |
| % Margin | – | – | – | -524,539.7% |
| Net Income | -$2,255 | $6,032 | -$1,476 | -$3,483 |
| % Margin | – | – | – | -570,922.8% |
| EPS Diluted | -0.023 | 0.12 | -0.045 | -0.11 |
| % Growth | -118.9% | 365.5% | 58.9% | – |
| Operating Cash Flow | -$10,249 | $4,690 | -$1,722 | -$2,433 |
| Capital Expenditures | -$17 | -$65 | -$39 | -$72 |
| Free Cash Flow | -$10,265 | $4,625 | -$1,762 | -$2,505 |